RESPITE trial

Remifentanil intravenous patient controlled analgesia (PCA) versus intramuscular Pethidine for pain relief in labour.

THE MAIN TRIAL FEATURES:

  • A randomised controlled trial.
  • Funded by the National Institute for Health Research (NIHR).
  • Run by Matthew Wilson (Chief Investigator).
  • Taking place primarily at Birmingham Women's Hospital in the West Midlands, but will be roled out to centres nationwide.
  • Birmingham Clinical Trials Unit at the University of Birmingham will be overseeing the administrative side of the Trial.
  • It is hoped that 400 patients will be recruited over a 20 month period beginning in March 2014.
  • Participating women will be randomly allocated either Pethidine injection OR Remifentanil patient controlled analgesia pain relief during labour.
  • The primary outcome will be the proportion of women, in each arm, that go on to need epidural analgesia.
  • Patients will receive quality of life questionnaires to complete during their admission, but will not need to be followed up after discharge.
  • The Trial is designed to fit in with routine hospital practice as far as possible.

 

For the latest Patient Information Leaflet click here

For a list of frequently asked questions click here